The study of the safety and effect of high dose allopurinol on the clinical, laboratory and echocardiographic variables in patients with severe left ventricle systolic dysfunction

The aim of the study is to evaluate the safety and effect of high dose allopurinol on the clinical, laboratory and echocardiographic variables in patients with severe left ventricle systolic dysfunction. In this clinical trial study 30 patients referring to Rajaie cardiovascular medical and research center heart failure clinics from 18 to 80 years old who had severe heart failure and New York heart association functional class II-III and had informed consent for participating in the study were included. Patients must have had a complete optimal treatment for at least one month before entrance into the study. The diagnosis of severe left ventricular systolic dysfunction is according to the echocardiography done by a single echocardiologist and is defined as Left ventricle ejection fraction of less than 35%. The exclusion criteria are glomerular filtration rate of less than 60ml/min, gout, severe liver failure, patients without informed consent or those that have had sensitivity to allopurinol. Allopurinol is started with the dose of 600 mg daily in patients not taking it and increased to this dose in patients taking the medicine from before. The patients are observed for 3 three months. They have initial echocardiographic evaluation, strain imaging, laboratory testing and 6 minute walk test. And after 3 months they again have complete echocardiographic evaluation, strain imaging, laboratory testing and 6 minute walk test. The main adverse effects that will be noted are skin rashes and gasterointestinal problems.

Rajaie cardiovascular medical and research center